Corbus Pharmaceuticals
CRBP
107 hedge funds and large institutions have $243M invested in Corbus Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 19 reducing their positions, and 30 closing their positions.
116% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 19
21% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $18.9M
0% more funds holding
Funds holding: 107 → 107 (0)
0% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 30
2.9% less ownership
Funds ownership: 100.59% → 97.69% (-2.9%)
50% less capital invested
Capital invested by funds: $486M → $243M (-$243M)
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$46.7M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$32.1M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$30.7M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$17.9M |
| 5 |
ACM
Altium Capital Management
New York
|
+$9.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$17M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$14.3M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$11.3M |
| 4 |
SCM
Sio Capital Management
New York
|
-$10.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
126
Prelude Capital Management
New York
| – | -$654K | -14,446 | Closed |
|
|
EI
127
EAM Investors
Solana Beach,
California
| – | -$571K | -12,609 | Closed |
|
|
JF
128
Jump Financial
Chicago,
Illinois
| – | -$555K | -12,272 | Closed |
|
|
GGHC
129
Gilder Gagnon Howe & Co
New York
| – | -$513K | -11,328 | Closed |
|
130
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$393K | -8,682 | Closed |
|
131
Invesco
Atlanta,
Georgia
| – | -$216K | -4,784 | Closed |
|
132
Simplex Trading
Chicago,
Illinois
| – | -$88.4K | -1,727 | Closed |
|
133
Pacer Advisors
Malvern,
Pennsylvania
| – | -$5.97K | -132 | Closed |
|
|
NS
134
NBC Securities
Birmingham,
Alabama
| – | -$1K | -33 | Closed |
|
|
UWS
135
Unique Wealth Strategies
Burr Ridge,
Illinois
| – | -$1.29K | -33 | Closed |
|
|
CA
136
CoreCap Advisors
Southfield,
Michigan
| – | -$1.13K | -25 | Closed |
|
|
SA
137
Scarborough Advisors
Annapolis,
Maryland
| – | -$272 | -6 | Closed |
|
CRBP Hedge Fund Activity: Q3 2024 in Review
107 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2024, worth a combined $243M — down 50% from $486M a quarter earlier.
Fund positioning in CRBP was balanced in Q3 2024: 30 funds opened new positions, 30 closed out, 41 added to existing stakes and 19 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $46.7M. The largest seller was Citadel Advisors, exiting entirely with an estimated $17M sold.
- 107 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $243M of Corbus Pharmaceuticals stock for Q3 2024, down 50% quarter-over-quarter.
- 30 funds opened new Corbus Pharmaceuticals positions in Q3 2024 and 30 closed out, a net change of 0 holders.
- The largest Corbus Pharmaceuticals buyer in Q3 2024 was OrbiMed, an estimated $46.7M added.
- The largest Corbus Pharmaceuticals seller in Q3 2024 was Citadel Advisors, an estimated $17M sold.
Based on aggregated 13F filings for Q3 2024.